This came up early and often during the Reagan-Udall Foundation’s public meeting on Wednesday, “Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub,” that brought together rare disease patient advocates, academic researchers, regulated industry, and other key stakeholders to discuss how the hub can best engage with members of the rare disease community and prioritize its work.

So with MDMA-AT off the table, where does the field go next? A public meeting in September hosted by the Reagan-Udall Foundation for the FDA in sought to answer that question.

The industry, consumer and state regulatory members of the Fresh Produce Coalition (FPC) are pleased that the U.S. Food and Drug Administration is supporting the Reagan-Udall Foundation’s (RUF) facilitation of an inclusive stakeholder dialogue to explore new strategies for produce safety.

Complex and disparately funded regulatory oversight for food and beverage products, spread out among many federal agencies, has created a regulatory mess that demands a radical fix.